LXRP - Lexaria Bioscience Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.9800
-0.0200 (-2.00%)
At close: 3:57PM EDT
Stock chart is not supported by your current browser
Previous Close1.0000
Open0.9850
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.9500 - 1.0000
52 Week Range0.7500 - 2.4300
Volume21,902
Avg. Volume114,785
Market Cap76.819M
Beta (3Y Monthly)2.78
PE Ratio (TTM)N/A
EPS (TTM)-0.0870
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • ACCESSWIRE4 days ago

    Lexaria’s DehydraTECH Formulation Delivers 475% More CBD to Bloodstream after 15 Minutes than Conventional Industry Formulations

    Lexaria's DehydraTECH formulation delivers cannabinoids at industry-leading volumes and speed while effectively masking bitter flavor and aroma profiles. KELOWNA, BC / ACCESSWIRE / May 15, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, has proven in animal testing that Lexaria's DehydraTECHTM technology delivers cannabinoids to the bloodstream much more quickly and effectively than conventional industry cannabinoid edible formulation designs that often combine cannabinoids with MCT oils such as coconut oil.

  • ACCESSWIRE12 days ago

    Lexaria Bioscience Announces CBD-Beverage Formulation License Agreement with Nevada-Based Company

    KELOWNA, BC / ACCESSWIRE / May 7, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, announces that it has entered a definitive 5-year agreement, via its subsidiary Lexaria Hemp Corp, to provide Lexaria's patented DehydraTECHTM technology to a private Nevada-based company for its utilization in certain CBD-based beverages to be produced and sold across the USA. Lexaria has developed methods of combining nano-emulsion technology with its proprietary DehydraTECH processes to create beverages with market-leading aesthetic and performance characteristics. Lexaria continues to experience strong demand in North American markets for use of its technology for beverage applications.

  • ACCESSWIRE24 days ago

    Lexaria Bioscience Expands Advisory Board

    KELOWNA, BC / ACCESSWIRE / April 25, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, is pleased to announce new appointments to its Scientific Advisory Board, each of whom will contribute advice and recommendations and support related to the Company's scientific research and product development. Lexaria is honored to have the opportunity of working with each of them. Dr. Dwayne Godwin is Dean of the Graduate School and Professor in the Departments of Neurobiology and Anatomy and the Institute for Regenerative Medicine at Wake Forest University.

  • ACCESSWIRE25 days ago

    Lexaria Bioscience Announces Beverage License Agreement with California-Based Cannabis Company

    KELOWNA, BC / ACCESSWIRE / April 24, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, announces that it has entered a definitive 5-year agreement, via its subsidiary Lexaria CanPharm ULC, to provide Lexaria's patented DehydraTECHTM technology to a private California-based cannabis company for its utilization in certain cannabis-based beverages to be produced and sold in the states of California and Nevada. Lexaria has developed methods of combining nano-emulsion technology with its proprietary DehydraTECH processes to create beverages with market-leading aesthetic and performance characteristics. Lexaria is currently experiencing unprecedented demand in several North American markets for use of its technology for beverage applications.

  • ACCESSWIRElast month

    Lexaria Bioscience Engages Oak Hill Financial Inc. to Provide Investor Relations Services

    KELOWNA, BC / ACCESSWIRE / April 15, 2019 / Lexaria Bioscience Corp. (LXX.CN) (LXRP) ("Lexaria" or the "Company") announces it has retained Oak Hill Financial Inc. ("OakHill") to provide investor relations services to the Company in compliance with regulatory guidelines. Oak Hill is a Toronto-based firm that develops strategic platforms for its clients that are utilized to gain exposure and recognition in the capital markets. Oak Hill provides asset management, capital market, and investor relations services.

  • ACCESSWIRElast month

    Lexaria Bioscience Renews Contracts with Senior Management and Cancels Options

    KELOWNA, BC / ACCESSWIRE / April 9, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, announces that it has successfully negotiated renewal management contracts with Chief Executive Officer Chris Bunka and President John Docherty. The new contracts are for 3-year terms and ensure that the Company can seamlessly pursue its business goals and create shareholder value while providing management continuity during this period of corporate growth. Lexaria will always strive to provide excellence in management which is always aligned with the interests of shareholders.

  • Newsfile2 months ago

    BTV Highlights 5 Companies Spearheading Innovation

    Vancouver, British Columbia--(Newsfile Corp. - March 28, 2019) - On national TV Sat Mar. 30 & Sun Mar. 31, 2019 - BTV- Business Television visits five inventive small cap companies leading advancements in their sectors. Full EpisodeNexTech AR Solutions (CSE: NTAR) (OTCQB: NEXCF) - BTV shares how this company's AR - Augmented Reality technology is disrupting the world of e-commerce . See Feature High Tide Inc. (CSE: HITI) - BTV ...

  • Newsfile2 months ago

    Lexaria Bioscience Corp., Ingesting Instead of Inhaling Could Save 60,000 Lives a Year, CEO Clip Video

    Vancouver, British Columbia--(Newsfile Corp. - March 22, 2019) - Chris Bunka, CEO of Lexaria Bioscience shares the company's unique opportunity to make ingesting any number of drugs and molecules healthier with their DehydraTECH technology.If you cannot view the video above, please visit:https://www.b-tv.com/lexaria-bioscience-ceo-clip-90sec/ Lexaria Bioscience Corp. is being featured on BNN Bloomberg on Mar. 23 - Mar. 24, 2019, throughout the day and evenings.Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)www.lexariabioscience.com About CEO ...

  • ACCESSWIRE2 months ago

    Lexaria Bioscience Begins Largest Cannabinoid R&D Program in its History

    KELOWNA, BC / ACCESSWIRE / March 20, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces that work has commenced on its largest-ever cannabinoid research program, which will also test Lexaria-designed nanotech enhancements. This new program is comprised of 11 separate animal studies, each of which is comparable in scope to individual animal studies conducted by the Company during 2018. Lexaria began its 2019 in vivo study design six months ago and laboratory test articles have all been produced and exceed all required quality control thresholds.

  • ACCESSWIRE3 months ago

    Lexaria Bioscience Comments on FDA Statement on Novel Nicotine Replacement Therapies

    KELOWNA, BC / ACCESSWIRE / February 26, 2019 / Lexaria Bioscience Corp. (LXRP) (CSE:LXX) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, comments on the February 21, 2019 U.S. Food & Drug Administration (''FDA") statement outlining the development of safe and effective novel nicotine replacement therapies to help smokers quit cigarettes, and the FDA draft guidance issued: ''Smoking Cessation and Related Indications: Developing Nicotine Replacement Therapy Drug Products''. Lexaria has recently partnered with a world-leading tobacco company that has licensed the Company's DehydraTECHTM technology to develop novel oral nicotine products utilizing Lexaria's technology that could harmonize with the evolving FDA strategy.

  • ACCESSWIRE3 months ago

    Cardiovascular Performance Improvements including Lower Blood Pressure Discovered from Human Clinical Trial using Lexaria's DehydraTECH(TM) Powered TurboCBD(TM) Capsules

    KELOWNA, BC / ACCESSWIRE / February 21, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, is pleased to announce additional significant findings upon completion of further data analyses from its 2018 randomized, placebo-controlled, double-blinded European human clinical study that evaluated TurboCBD™, the Company's proprietary, DehydraTECH™ powered, cannabidiol (''CBD'') fortified hemp-oil capsule.

  • Newsfile4 months ago

    CannabisNewsAudio Announces Audio Press Release (APR) on Lexaria Bioscience Corp. Creating Subsidiaries, Carving Opportunity in Global Cannabis Industry

    New York, New York--(Newsfile Corp. - February 1, 2019) - CannabisNewsAudio announces the Audio Press Release (APR) titled "Outside Investment, New Technology Support Growing Cannabis Industry," featuring Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP).To hear the CannabisNewsAudio version, visit: http://cnw.fm/uXf6S To read the full editorial, visit: http://cnw.fm/H3q7rTo make the most of this potential, Lexaria has created subsidiaries specializing in the use of DehydraTECH for cannabis. Lexaria CanPharm Corporation focuses on the cannabis market, providing ...

  • GlobeNewswire4 months ago

    CannabisNewsAudio Announces Audio Press Release (APR) on Lexaria Bioscience Corp. Gaining Appeal in Cannabis Edibles with DehydraTECH

    NEW YORK, Feb. 01, 2019 -- via CannabisNewsWire – CannabisNewsAudio announces the Audio Press Release (APR) titled “Outside Investment, New Technology Support Growing Cannabis.

  • GlobeNewswire4 months ago

    CannabisNewsWire Announces Publication on Cannabis Industry Innovations and Advancements Drawing Investment from Big Corporations

    NEW YORK, Jan. 31, 2019 -- via CannabisNewsWire – CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company, today announces the publication of an.

  • GlobeNewswire4 months ago

    NetworkNewsAudio Announces Audio Press Release (APR) on Lexaria Bioscience Corp.’s Proprietary Technology Levels Field with Big Players in Bioscience

    NEW YORK, Jan. 23, 2019 -- via NetworkWire – NetworkNewsAudio announces the Audio Press Release (APR) titled “Definitive Agreement Marks Milestone for Alternative Nicotine.

  • GlobeNewswire4 months ago

    NetworkNewsWire Announces Publication on Innovators at the Door of Big Tobacco in Quest for Cigarette Alternatives

    NEW YORK, Jan. 17, 2019 -- via NetworkWire — NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial.

  • GlobeNewswire4 months ago

    Altria Group Invests Up to $12M in Lexaria Bioscience’s DehydraTECH™ Technology

    KELOWNA, British Columbia, Jan. 17, 2019 -- via NetworkWire -- Lexaria Nicotine LLC, a wholly owned subsidiary of Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX), has entered.

  • Newsfile4 months ago

    Altria Group Invests Up to $12M in Lexaria Bioscience's DehydraTECH(TM) Technology

    Kelowna, British Columbia--(Newsfile Corp. - January 17, 2019) - Lexaria Nicotine LLC, (OTCQX: LXRP) (CSE: LXX) a wholly owned subsidiary of Lexaria Bioscience Corp. has entered into a definitive agreement with Altria Group Inc. (NYSE: MO) to fund the research & development of Lexaria's patented DehydraTECH™ technology. Lexaria's DehydraTECH™ enhances the performance of beneficial compounds in ingestible products across four categories: taste & smell, speed of action, bio-absorption and bioavailability. The partnership will ...

  • ACCESSWIRE4 months ago

    Lexaria Bioscience Announces Partnership with Altria to Fund Research and Development of DehydraTECH(TM) Technology for Oral Nicotine

    Lexaria Nicotine LLC and a subsidiary of Altria Group, Inc. have entered into a definitive investment agreement. The Altria investment will fund research on regulatory compliant, oral forms of nicotine ...

  • GlobeNewswire4 months ago

    Exclusive Interview: Lexaria CEO Discusses Progress & Plans at O’Cannabiz 2018 -- CFN Media

    SEATTLE, Jan. 09, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Lexaria Biosciences Inc. (CSE:LXX) (CN) (CNSX:LXX) (LXRP). The company is a developer of drug delivery technologies for bioactive compounds, Lexaria is one of the oldest companies in the cannabis industry.

  • ACCESSWIRE5 months ago

    Lexaria Bioscience Expands Staff, Issues Options

    KELOWNA, BC / ACCESSWIRE / December 7, 2018 / Lexaria Bioscience Corp. (LXRP) (CNSX:LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces the following updates. In the New Year, Lexaria expects to begin hiring additional new laboratory personnel as its R&D operations intensify. As a result of the latest positions created, Lexaria is issuing 240,000 stock options with an exercise price of US$1.06, that will vest as to 80,000 per year until April 15, 2021.

  • Newsfile6 months ago

    CannabisNewsAudio Announces Audio Press Release (APR) on Lexaria Bioscience Corp. Holds Enviable Position in Rise of Cannabis Edibles

    New York, New York--(Newsfile Corp. - November 30, 2018) -  CannabisNewsAudio announces the Audio Press Release (APR) titled "Booming Cannabis Consumables Space Continues to See Product Innovations," featuring Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP).To hear the CannabisNewsAudio version, visit: http://cnw.fm/IxM3OTo read the full editorial, visit: http://cnw.fm/qzN9LLexaria's proprietary technology is patent protected for CBD and other nonpsychoactive cannabinoids and has patents pending for THC, other psychoactive cannabinoids, NSAIDs (non-steroidal anti-inflammatory drugs), nicotine and other ...

  • GlobeNewswire6 months ago

    CannabisNewsAudio Announces Audio Press Release (APR) on Lexaria Bioscience Corp. Capitalizing on Technology in CBD-Infused Products

    NEW YORK, Nov. 30, 2018 (GLOBE NEWSWIRE) -- via CannabisNewsWire – CannabisNewsAudio announces the Audio Press Release (APR) titled “Booming Cannabis Consumables Space Continues to see Product Innovations,” featuring Lexaria Bioscience Corp. (CSE:LXX) (LXRP). Capitalizing on its bioavailability-enhancing technology and established presence as a CBD-infused product developer, Lexaria has now moved to tackle the U.S. soft drinks market, which is expected to be worth $388 billion-plus by 2025, introducing a discreet, single-serving foil packet cannabinoid drink powder named ChrgD+. Lexaria is confident that a small two-gram foil packet that can be discreetly carried in a shirt pocket or purse for incorporation into a beverage will be a big hit.

  • GlobeNewswire6 months ago

    CannabisNewsWire Announces Growing Cannabis Acceptance Setting Stage For Consumable Cannabis Boom

    NEW YORK, Nov. 29, 2018 -- via CannabisNewsWire -- CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company, today announces the publication of an.

  • ACCESSWIRE6 months ago

    Lexaria Bioscience Submits Application to Health Canada for Research License and Appoints Chief Legal Officer

    KELOWNA, BC / ACCESSWIRE / November 26, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces it has submitted a Health Canada research application, and appointed Dr. Ed Ergenzinger to its executive team. The Company has submitted its research application under Health Canada's Cannabis Tracking and Licensing System for the operation of a Kelowna-based R&D laboratory within Lexaria's new head office under construction, to work with cannabinoids. The laboratory will enhance Lexaria's ability to formulate for analytical purposes, various products that may contain cannabinoids or other controlled substances.